We are live on ! Find out more
TNDM icon

Tandem Diabetes Care

284 hedge funds and large institutions have $3.24B invested in Tandem Diabetes Care in 2019 Q4 according to their latest regulatory filings, with 45 funds opening new positions, 85 increasing their positions, 101 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more capital inflows, than outflows

Capital inflows: $665M | Capital outflows: $445M

16% more call options, than puts

Call options by funds: $46.2M | Put options by funds: $39.7M

14% more funds holding in top 10

Funds holding in top 10: 7 → 8 (+1)

7.28% more ownership

Funds ownership: 84.75% → 92.03% (+7.3%)

4% more funds holding

Funds holding: 273 → 284 (+11)

0% more first-time investments, than exits

New positions opened: 45 | Existing positions closed: 45

16% less repeat investments, than reductions

Existing positions increased: 85 | Existing positions reduced: 101

Holders
284
Holders Change
+11
Holders Change %
+4.03%
% of All Funds
5.58%
Holding in Top 10
8
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+14.29%
% of All Funds
0.16%
New
45
Increased
85
Reduced
101
Closed
45
Calls
$46.2​M
Puts
$39.7​M
Net Calls
+$6.48​M
Net Calls Change
+$2.46​M

TNDM Hedge Fund Activity: Q4 2019 in Review

284 of the 5,090 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q4 2019, worth a combined $3.24B — up 11% from $2.93B a quarter earlier.

Fund positioning in TNDM was balanced in Q4 2019: 45 funds opened new positions, 45 closed out, 85 added to existing stakes and 101 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $92.2M. The largest seller was Renaissance Technologies, cutting an estimated $37.5M.

  • 284 institutional investors held Tandem Diabetes Care (TNDM) as of Q4 2019, up from 273 in Q3 2019.
  • Funds reported $3.24B of Tandem Diabetes Care stock for Q4 2019, up 11% quarter-over-quarter.
  • 45 funds opened new Tandem Diabetes Care positions in Q4 2019 and 45 closed out, a net change of 0 holders.
  • The largest Tandem Diabetes Care buyer in Q4 2019 was Fidelity Investments, an estimated $92.2M added.
  • The largest Tandem Diabetes Care seller in Q4 2019 was Renaissance Technologies, an estimated $37.5M sold.

Based on aggregated 13F filings for Q4 2019.